GENERAL HEMATOLOGY

Feature

Interferon Alfa Combination Therapy for the Treatment of Myeloproliferative Neoplasms

Though IFN alfa-2 has been shown to be effective in treating MPNs, it is not the therapy of choice outside of Europe.

Latest News

Single-Allele Mismatch May Decrease Non-Relapse Mortality in Unrelated Bone Marrow Transplantation

By

A single-allele mismatch was associated with decreased risk of non-relapse mortality and overall mortality compared with a single-antigen mismatch.

Cytarabine as a Chemotherapeutic Agent for Autologous Stem Cell Transplantation in Patients With Multiple Myeloma

By

Intermediate-dose cytarabine has been demonstrated to have high efficacy as a chemomobilization agent.

Hemochromatosis Penetrance Decreased Over Time in French Cohort

By

Though patients tended to be older at diagnosis, the severity of genetic hemochromatosis has decreased over time.

Incidence and Prognostic Value of Cytogenetic Abnormalities in Systemic Mastocytosis

By

The prognostic value of karyotype in systemic mastocytosis, especially in the presence of adverse mutations, is unclear.

Peripheral Blood: An Alternative Source of Stem Cells in Thalassemia

By

Accessing peripheral blood as a graft source is easier and less invasive than accessing bone marrow.

Intravenous Immunoglobulin Associated With Hemolytic Anemia in Kawasaki Disease

By

Kawasaki is a rare hematologic disease that occurs in fewer than 20,000 patients in the United States annually.

Interferon Alfa Combination Therapy for the Treatment of Myeloproliferative Neoplasms

By

Though IFN alfa-2 has been shown to be effective in treating MPNs, it is not the therapy of choice outside of Europe.

Ruxolitinib Plus Azacitidine May Benefit Patients With Myelofibrosis

By

The combination of the 2 drugs seems to display synergistic effects.

Screening First-Degree Relatives of Multiple Myeloma Patients May Point to New Prevention Strategies

By

Screening first-degree relatives of patients with MM may be a viable prevention strategy.

Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis

By James Nam, PharmD

In a phase 2 study, researchers assessed the efficacy of using a dose-escalation approach to lessen the occurrence and severity of anemia in MF treated with ruxolitinib.

Palliative Issues Inadequately Addressed Among Hospitalized Cancer Patients

By James Nam, PharmD

Consultations for palliative care for hospitalized highly symptomatic patients with cancer is low regardless of curability or whether patient has hematologic or solid cancer, a study presented at 2018 ASCO has shown.

Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers

By James Nam, PharmD

A newly developed web site, described in a presentation at the 2018 ONS Annual Congress, aims to help nurses and patients explore clinical trial options for patients with hematologic cancers.

First Generic Alternative for Mephyton Now Available

By Da Hee Han, PharmD

Amneal's generic product is available in a 5mg strength tablet supplied in 100-count bottles.

Praxbind Gains Full FDA Approval as Pradaxa Reversal Agent

By Da Hee Han, PharmD

Complete reversal was seen within 4 hours in the majority of patients, as measured by ecarin clotting time (ECT 82%) or diluted thrombin time (dTT 99%). In addition, there was a low late of thrombotic events and no new safety events were reported.

Patients Identify Critical Elements of Support in Hematologic Cancers

By James Nam, PharmD

A cross-sectional study asked patients with hematologic cancers to name the components of care they felt were most crucial to their perception of optimal care.

Pacritinib May Benefit Some Patients With Myelofibrosis

By Jonathan Goodman, MPhil

Researchers evaluated whether pacritinib would improve SVR and TSS compared with the best available therapy, including ruxolitinib.

Cognitive Impairment Worsens Survival Among Elderly Patients With Hematologic Cancer

By Jonathan Goodman, MPhil

A variety of cognitive impairments are common in the elderly US population, with as many as 14% of individuals over 70 being affected by dementia.

Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis

By James Nam, PharmD

A retrospective chart study demonstrated the effectiveness of fosfomycin as an antibacterial prophylaxis for febrile neutropenia in patients with hematologic cancer.

PAH Long-Term Survival Predicted by Reliable Risk Calculator

By Brandon May

Researchers examined the effect of riociguat compared with placebo on the REVEAL risk score and long-term outcomes for pulmonary arterial hypertension.

Vemurafenib Effective in BRAF-mutated Erdheim-Chester Disease and Langerhans Cell Histiocytosis

By James Nam, PharmD

Although patients with ECD and LCH frequently have BRAFV600 mutations and respond to BRAFV600 inhibitor therapy, there was previously a lack of data describing long-term efficacy and safety.

SIGN UP FOR FREE E-NEWSLETTERS